Breaking News, Promotions & Moves

Uniquity Bio Appoints Will Kane President and CEO

Kane will advance strategic priorities and advance Solrikitug, its lead asset, in Phase II trials and prepare for Phase III.

By: Rachel Klemovitch

Assistant Editor

Uniquity Bio, a clinical-stage drug development company backed by Blackstone Life Sciences, appointed Will Kane as President and CEO. Kane will support strategy and growth as Uniquity advances Solrikitug, its lead asset, in the completion of three Phase II trials and prepares for Phase III. Kane succeeds Brian Lortie, co-founder and former CEO, who stepped down from the company in June 2025.  Kane joins with more than three decades of biopharmaceutical leadership experience and a trac...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters